What is Brii Biosciences Limited?
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 135.73M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.